SCHEMBL6080124

SCHEMBL6080124

O=C(O)c1cc(O)c2cccc(CCc3ccccc3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAUR Q03405 1/20 0.45
SOX18 P35713 1/20 0.44
KDM4E B2RXH2 3/20 0.44
BID P55957 1/20 0.42
BCL2L1 Q07817 1/20 0.42
MCL1 Q07820 1/20 0.42
BAK1 Q16611 1/20 0.42
KMT2A Q03164 1/20 0.40
P2RX3 P56373 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
IGFBP3 P17936 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
HSD17B3 P37058 1/20 0.39
SLC16A3 O15427 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EP300 Q09472 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079986 0.86 HSP90AA1 (0.43) PLAURKDM4ETDP1ALDH1A1HPGD
SCHEMBL6080733 0.85 KDM4E (0.43) SOX18KDM4EP2RX3CSNK2A2CSNK2B
SCHEMBL6079288 0.85 KDM4E (0.51) SOX18KDM4EBIDBCL2L1MCL1
SCHEMBL6079837 0.81 P2RX3 (0.42) KDM4EKMT2AP2RX3CSNK2A2CSNK2B
SCHEMBL6080301 0.81 BID (0.54) KDM4EBIDBCL2L1MCL1BAK1
SCHEMBL6597624 0.78 KDM4E (0.41) PLAURKDM4EP2RX3CSNK2A2CSNK2B
SCHEMBL6604473 0.78 ALOX15 (0.54) KDM4EP2RX3CSNK2A2CSNK2BCSNK2A1
Xanthurenate SCHEMBL29911018 0.78 KDM4E (0.59) KDM4EKMT2AIGFBP3TDP1
Xanthurenate SCHEMBL379760 0.78 KDM4E (0.59) KDM4EKMT2AIGFBP3TDP1
Xanthurenate SCHEMBL29394132 0.78 KDM4E (0.59) KDM4EKMT2AIGFBP3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed
EP-1451159-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2004-09-01 EP disclosed
WO-2003010146-A1 COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF NEURO3D (FR) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL PLAUR 4883/4885SOX18 1015/4885KDM4E 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.